{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:41:48Z","timestamp":1779882108867,"version":"3.53.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejca.2024.113912","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T22:05:06Z","timestamp":1707516306000},"page":"113912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-5181","authenticated-orcid":false,"given":"Teresa","family":"Amaral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Nanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-6028","authenticated-orcid":false,"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-4945","authenticated-orcid":false,"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1611-9335","authenticated-orcid":false,"given":"Andreas","family":"Meiwes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Wolfsperger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Meraz-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7843-7160","authenticated-orcid":false,"given":"Eftychia","family":"Chatziioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.113912_bib1","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA: a Cancer J Clin"},{"key":"10.1016\/j.ejca.2024.113912_bib2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.113912_bib3","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.113912_bib4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.113912_bib5","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic therapy for Melanoma: ASCO guideline update","volume":"41","author":"Seth","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113912_bib6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.113912_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2022.06.054","article-title":"Reporting of melanoma cell densities in the sentinel node refines outcome prediction","volume":"174","author":"Ulmer","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113912_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001604","article-title":"Quantitative measurement of melanoma spread in sentinel lymph nodes and survival","volume":"11","author":"Ulmer","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2024.113912_bib9","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1158\/1078-0432.CCR-04-1995","article-title":"Detection of melanoma cells displaying multiple genomic changes in histopathologically negative sentinel lymph nodes","volume":"11","author":"Ulmer","year":"2005","journal-title":"Clin Cancer Res: J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2024.113912_bib10","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/annonc\/mdl176","article-title":"Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?","volume":"17","author":"van Akkooi","year":"2006","journal-title":"Ann Oncol: J Eur Soc Med Oncol \/ ESMO"},{"key":"10.1016\/j.ejca.2024.113912_bib11","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.22.00202","article-title":"Prognosis of patients with primary melanoma stage I and II According to American Joint Committee on Cancer Version 8 validated in two independent cohorts: implications for adjuvant treatment","volume":"40","author":"Garbe","year":"2022","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113912_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2023.3256","article-title":"Stage-specific risk of recurrence and death from Melanoma in Denmark, 2008-2021: a national observational cohort study of 25\u00a0720 patients with stage IA to IV Melanoma","author":"Helvind","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2024.113912_bib13","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1245\/s10434-011-2208-z","article-title":"Sentinel lymph nodes containing very small (<0.1 mm) deposits of metastatic melanoma cannot be safely regarded as tumor-negative","volume":"19","author":"Murali","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.113912_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2013.08.023","article-title":"The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients","volume":"50","author":"van der Ploeg","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113912_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2019.07.004","article-title":"Melanoma-specific survival in patients with positive sentinel lymph nodes: relevance of sentinel tumor burden","volume":"123","author":"Satzger","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113912_bib16","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.21.02488","article-title":"Clinical outcomes and risk stratification of early-stage Melanoma micrometastases from an International multicenter study: implications for the management of American Joint Committee on Cancer IIIA Disease","volume":"40","author":"Moncrieff","year":"2022","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113912_bib17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2022.03.008","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics: update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113912_bib18","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020\u2020Approved by the ESMO Guidelines Committee","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.113912_bib19","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113912_bib20","unstructured":"information E-Np. EMA - Nivolumab prescribing information. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.ejca.2024.113912_bib21","unstructured":"information E-Pp. EMA - Pembrolizumab prescribing information. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.ejca.2024.113912_bib22","unstructured":"information E-Dp. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tafinlar-epar-product-information_en.pdf\u3009. 2023."},{"key":"10.1016\/j.ejca.2024.113912_bib23","unstructured":"information E-Tp. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mekinist-epar-product-information_en.pdf\u3009. 2023."},{"key":"10.1016\/j.ejca.2024.113912_bib24","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.21.01107","article-title":"Isolated tumor cells in Sentinel Lymph Nodes: a management dilemma","volume":"39","author":"Kaul","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113912_bib25","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/PAS.0b013e3180341ebc","article-title":"Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes","volume":"31","author":"Satzger","year":"2007","journal-title":"Am J Surg Pathol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:29Z","timestamp":1760733809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924000881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":25,"alternative-id":["S0959804924000881"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113912","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113912"}}